Sector News

Lonza to expand development services for mammalian products in Singapore

October 10, 2021
Life sciences

Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, today announced it will invest to expand mammalian development services in Singapore. The expansion will establish additional capacity for cell culture, purification, and analytical services for mammalian biologics.

The increased service capabilities complement the existing offering, consisting of cell line construction services, process development and process characterization services at the mammalian and cell therapy manufacturing site in Singapore.

This investment will expand the current laboratory capabilities by establishing a new 1,800m2 laboratory at Singapore Science Park, increasing the headcount of the mammalian development services team in Singapore to 125 employees. The new laboratory began operations in September. As part of the investment, the existing laboratories at Lonza’s Tuas, Singapore site will be upgraded by the end of 2021.

Jeetendra Vaghjiani, Senior Director of Clinical Development for Mammalian Biologics, Lonza, commented: “The growth of our global manufacturing network brought a need to increase services supporting these assets. The investment to expand our mammalian manufacturing services in Singapore will ensure that our team continues to deliver timely support to our customers, in particular for process development and characterization studies necessary for advancing therapies towards regulatory approvals and commercialization.”

As part of the expansion, Lonza will invest in the latest technology for mammalian process and analytical development through the addition of systems for cell line development, the latest in perfusion and process analytical technology for process development, as well as providing the capability to perform extensive characterization of biopharmaceuticals using mass spectrometry for the first time in Singapore. The investment will also provide opportunities to expand the service offering and strengthen the position for the anticipated market growth in complex protein formats.

The addition of new technology, alongside the increase in capacity and headcount of Lonza’s development services team in Singapore, will provide a comprehensive offering for small- and large-scale GMP mammalian manufacturing services and cell therapy capabilities.

By Lonza, Press Release

Source: lonza.com

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend